Human alpha-beta T cell receptor (TCR (for T cell receptor, commonly used in the literature for αβ TCR specifically[5][1]))

The **human alpha-beta T cell receptor** (TCR) is a membrane-bound heterodimeric protein complex expressed on the surface of most T lymphocytes. The TCR typically consists of two distinct polypeptide chains, alpha (α) and beta (β), that form a highly diverse antigen-recognition receptor through V(D)J recombination. Each chain has a variable (V) and constant (C) domain, with their variable regions forming the antigen-binding site[1][5][3]. TCRs recognize peptide fragments presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells, and this binding triggers intracellular signaling via associated CD3 complex signaling subunits (CD3γ, CD3δ, CD3ε, and CD3ζ), which contain immunoreceptor tyrosine-based activation motifs (ITAMs) critical for downstream pathways[1][2][3][4]. TCR engagement drives T cell activation, proliferation, cytokine production, and differentiation, enabling adaptive immunity against pathogens and malignant cells. The integrity and regulation of TCR signaling are crucial for immune system function, and dysregulation is implicated in autoimmune disease, infection susceptibility, and the efficacy or toxicity of immunomodulatory therapies[4][3].

Other names

TCRαβ T cell receptorT-cell antigen receptor alpha/beta chainT cell receptor alpha/betaTCRαβ

T cell receptor targeting drugs (ex: bispecific antibodies such as blinatumomab, anti-CD3 therapies) function by redirecting or activating T cells based on engagement with the TCR-CD3 complex or downstream signaling components Immunotherapies may engineer T cells with chimeric antigen receptors (CAR-T) or transgenic TCRs specific for defined peptide/MHC complexes, which require functional human TCRαβ[4][1]